Sun Life Financial’s CytomX Therapeutics CTMX Stock Holding History

Sun Life Financial’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-19,637	Closed	-$145K	–	487
2019 Q3	$145K	Buy	+19,637	New	+$194K	0.04%	211

Other funds holding CTMX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sun Life Financial's CTMX Position: Q4 2019 in Review

Sun Life Financial sold out of CytomX Therapeutics (CTMX) in Q4 2019, closing a stake of 19,637 shares — an estimated $145K sold.

Sun Life Financial first reported a position in CTMX in Q3 2019 and held it in 1 quarter. The position peaked at $145K in Q3 2019. 119 funds tracked by Wall St. Rank hold CTMX as of Q4 2019.

Sun Life Financial reported no remaining CytomX Therapeutics position as of Q4 2019 after selling out during the quarter.
Sun Life Financial sold 19,637 CytomX Therapeutics shares in Q4 2019, an estimated $145K.
Sun Life Financial first reported a position in CytomX Therapeutics in Q3 2019 and held it in 1 quarter.
Sun Life Financial's CytomX Therapeutics position peaked at $145K in Q3 2019.
119 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q4 2019.

Based on Sun Life Financial's 13F filing for Q4 2019, filed 10 Feb 2020.